Industry Insight
Discovery Technology
Analytical Laboratory Technology
Delivery Systems
Ingredients, Formulation and Finishing
View our other publications with free access to extensive archives


 29th April 2010 Evotec

EVOTEC WINS RESEARCH GRANT TO ADVANCE H3 RECEPTOR ANTAGONIST PROGRAMME INTO THE CLINIC Hamburg, Germany – 27 April 2010: Evotec AG (Frankfurt Stock Ex-change: EVT, TecDAX) today announced that it will receive funding of up to EUR 1.5 million from the German Federal Ministry of Education and Research (BMBF) to advance its H3 receptor antagonist programme into the clinic. Using its CNS expertise coupled with its world leading discovery platform Evotec has successfully identified and optimised H3 receptor antagonists through to preclinical development. This grant will now provide external funding for Evotec to advance the programme through Phase I clinical studies. The histamine H3 receptor is a drug target of high interest because of evidence that blocking this receptor in the brain can improve cognition, alertness and attention. H3 receptor antagonists therefore have the potential to become an important new class of therapy in a number of CNS indications, including excessive fatigue associated with conditions such as multiple sclerosis. Dr Werner Lanthaler, Chief Executive Officer of Evotec commented: “We are happy that the Neu˛ consortium has chosen to support our H3 receptor antagonist programme for further development within the BioPharma initiative. By driving these novel drug candidates from identification through to the first clinical steps, we can optimally capture the commercial value of this programme.” About Neu2 Consortium The Neu2 consortium, including Evotec, MerckSerono, the European ScreeningPort GmbH, Bionamics GmbH, and the University Medical Center Hamburg-Eppendorf amongst others were successful against stiff competition in the BioPharma initiative, a nationwide strategic competition of the BMBF with the objective to support innovative drug discovery programmes in the German Pharma and Biotech industry. Evotec plays an important role in the Neu2 consortium which focuses on developing therapeutics aimed at multiple sclerosis and other neurodegenerative diseases. About Evotec AG Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialised platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, oncology and inflammation. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression. For additional information please go to For more information, please contact: Tristan Jervis or Alex Heeley on 00 44 207 861 3838. E-mail: t.jervis|


Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |